123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> Health >> View Article

Medimmune: Collaboration With Trellis Strengthens Rsv Pipeline

Profile Picture
By Author: Sandhya
Total Articles: 1486
Comment this article
Facebook ShareTwitter ShareGoogle+ ShareTwitter Share

MedImmune: collaboration with Trellis strengthens RSV pipeline

MedImmune has agreed to license the rights to develop Trellis Bioscience's monoclonal antibody products for the treatment of respiratory syncytial virus (RSV). MedImmune already has one RSV product on the market and has filed for motavizumab, its follow-on compound. However, the efficacy of both products can be improved upon, which may have driven MedImmune's decision to collaborate with Trellis. ( http://www.bharatbook.com/detail.asp?id=124900&rt=Monoclonal-antibodies-2009-update.html )

Trellis Bioscience has granted a worldwide exclusive license to MedImmune, the global biologics unit of AstraZeneca, to develop and commercialize Trellis' antibodies directed against the respiratory syncytial virus (RSV). The RSV antibodies were discovered using Trellis' proprietary CellSpot discovery platform which enables rapid identification and isolation of human antibodies produced from the B-cells of RSV-infected patients. The deal's value could reach $338 million if a product reaches the market.

MedImmune already has one marketed RSV antibody product ...
... (Synagis; palivizumab), which is currently the only available drug for prophylaxis of RSV infection. Synagis was approved in June 1998 for the prevention of serious respiratory disease caused by RSV in infants and children with a history of preterm birth (less than or equal to 35 weeks' gestation) or chronic liver disease (CLD). While it has successfully reduced RSV hospitalizations in this high risk population, its clinical efficacy can still be improved upon.

Recognizing Synagis' shortcomings, MedImmune developed a follow-on compound, motavizumab. This antibody has to-date demonstrated non-inferiority to Synagis but does not offer any significant improvements in terms of efficacy. The company filed for approval of motavizumab in January 2008 but received a Complete Response Letter (CRL) from the FDA asking for additional information. It is yet unclear whether MedImmune has addressed the regulator's questions.

In addition to motavizumab, the company is also developing an extended half-life RSV monoclonal antibody, two vaccines for RSV prophylaxis and an F-protein inhibitor for the treatment of RSV infection. MedImmune's collaboration with Trellis comes as a logical step considering the attractive market gap for RSV therapies with improved efficacy.

Given that motavizumab does not offer any significant therapeutic benefits over Synagis and the extended release version will only offer improvements in terms of administration, it is likely that MedImmune will develop Trellis' RSV antibodies as successors to motavizumab and may also use them in combination with other RSV products. Other companies with RSV products in development include Pevion Biotech which has an RSV vaccine in preclinical stages, and Cubist Pharmaceuticals which is developing Alnylam's RNAi-based RSV inhibitors.

Related research

Monoclonal antibodies: 2009 update
http://www.bharatbook.com/detail.asp?id=124900&rt=Monoclonal-antibodies-2009-update.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook

Total Views: 308Word Count: 433See All articles From Author

Add Comment

Health Articles

1. Top Chiropractic Billing Mistakes That Hurt Your Practice’s Revenue
Author: infohubconsultancy

2. A Comprehensive Guide To Pet Respiratory Support
Author: VetSupply

3. Are Premium Supplements Worth The Price? Benefits Of Best Health Supplement
Author: John Smith

4. Exploring How Digital Imaging Has Revolutionized Diagnostic Processes
Author: Vheartcare

5. Discover Comfortable Root Canal Care For A Healthy Smile
Author: Dr Abhilash

6. Choosing The Right Hair Transplant Clinic In Ahmedabad: What To Know In 2025
Author: new touch

7. Pet Pain Relief: The Complete Vet-approved Guide For Caring Pet Parents
Author: VetSupply

8. What Is Implant Supported Overdenture?
Author: Perio PDX

9. Ivf Centre In Saudi Arabia: Global Choices From Uae To South Africa For Your Parenthood Journey
Author: Juhi Fertility

10. Top Occurrence Codes Used In Snf Billing And What They Mean
Author: Charlie Robinson

11. For Effective Weight Loss And A Fit Body And Mind Get Enrolled In A Weight Loss Clinic!
Author: Alexis Pelloe

12. Enjoy An Adult Massage To Calm Your Mind And Soul
Author: Emma Brain

13. From Tooth Loss To Confidence: The Impact Of Dental Prosthetics
Author: Ansley Colton

14. Nitrous Oxide Vs. Oral Sedation For Kids: Which Is Safer?
Author: Pat

15. Dr. Tirumala Prasad: The Foremost Robotic Surgeon
Author: Dr.Tirumala Prasad

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: